Capricor surges as FDA resumes review of muscle‑wasting disease drug

Capricor Therapeutics

10/03/2026 13:55

** Shares of drug developer Capricor Therapeutics CAPR.O rise 15.4% to $35.2

** CAPR says U.S. FDA has lifted its complete response letter and resumed review of deramiocel, CAPR's therapy for Duchenne muscular dystrophy

** Duchenne muscular dystrophy is a genetic disease that weakens muscles and affects the heart

** FDA said in its complete response letter last August the data submitted for deramiocel did not meet efficacy requirements and asked the company to provide additional evidence

** Co says the FDA has set a target action date of August 22, 2026, after reviewing late-stage data that the company disclosed last year

** Including session's move, CAPR stock was up 17.3% YTD

(Reporting by Sahil Pandey and Padmanabhan Ananthan in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))